Don't Buy Halozyme Therapeutics Before Checking Its Fundamentals!

By Chris Stiles • Wednesday, November 29 17:00 • Permanent Link

One of the losers of today's trading session was Halozyme Therapeutics. Shares of the Biotechnology company plunged -3.0%, and some investors may be wondering if its price of $38.5 would make a good entry point. Here's what you should know if you are considering this investment:

Halozyme Therapeutics has moved -33.0% over the last year, and the S&P 500 logged a change of 12.0%
HALO has an average analyst rating of buy and is -24.91% away from its mean target price of $51.27 per share
Its trailing earnings per share (EPS) is $1.87
Halozyme Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 20.6 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $4.34 and its forward P/E ratio is 8.9
The company has a Price to Book (P/B) ratio of 20.4 in contrast to the S&P 500's average ratio of 2.95
Halozyme Therapeutics is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
HALO has reported YOY quarterly earnings growth of 38.6% and gross profit margins of 0.7%
The company has a free cash flow of $301.06 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.